Compare FLYX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLYX | TENX |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 74.1M |
| IPO Year | 2021 | 2001 |
| Metric | FLYX | TENX |
|---|---|---|
| Price | $1.21 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 159.8K | ★ 1.9M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $375,877,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $15.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.85 | N/A |
| 52 Week Low | $1.05 | $1.31 |
| 52 Week High | $8.88 | $19.40 |
| Indicator | FLYX | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 44.27 |
| Support Level | $1.09 | $1.34 |
| Resistance Level | $1.38 | $2.00 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 53.85 | 65.38 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.